The company has consolidated its position in GCC, ASEAN, Balkan and Caribbean regions with marketing approvals from Oman, Malaysia, Bosnia and Trinidad & Tobago for important chemotherapy drugs With this, the number of marketing approvals for its oncology products across 75 countries has gone